What we know — and don’t know — about Merck’s new Covid-19 pill.

What we know — and don’t know — about Merck’s new Covid-19 pill – STAT

Related:

[Press release – not published yet] Merck announces oral antiviral Molnupiravir reduced the risk of hospitalization or death by approximately 50 Percent compared to placebo for patients with mild or moderate COVID-19.

Merck’s Covid-19 pill is great news but may not be a game-changer.

Video | A Pill For COVID? A Doctor Explains Molnupiravir.